Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Use of a decision-analytic model to support the use of a new oral US contrast agent in patients with abdominal pain
Autore:
Bree, RL; Arnold, RJG; Pettit, KG; Kaniecki, DJ; OHaeri, C; LaFrance, ND; Toaff, AL;
Indirizzi:
Univ Missouri Hosp & Clin, Dept Radiol, Columbia, MO 65212 USA Univ Missouri Hosp & Clin Columbia MO USA 65212 l, Columbia, MO 65212 USA Bracco Diagnost, Princeton, NJ USA Bracco Diagnost Princeton NJ USABracco Diagnost, Princeton, NJ USA Thomas Jefferson Univ Hosp, Dept Radiol, Philadelphia, PA 19107 USA ThomasJefferson Univ Hosp Philadelphia PA USA 19107 elphia, PA 19107 USA
Titolo Testata:
ACADEMIC RADIOLOGY
fascicolo: 3, volume: 8, anno: 2001,
pagine: 234 - 242
SICI:
1076-6332(200103)8:3<234:UOADMT>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
COST-EFFECTIVENESS ANALYSIS;
Keywords:
contrast media; contrast media, comparative studies; ultrasound, comparative studies; ultrasound (US), contrast media;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
16
Recensione:
Indirizzi per estratti:
Indirizzo: Bree, RL Univ Missouri Hosp & Clin, Dept Radiol, Columbia, MO 65212 USA Univ Missouri Hosp & Clin Columbia MO USA 65212 ia, MO 65212 USA
Citazione:
R.L. Bree et al., "Use of a decision-analytic model to support the use of a new oral US contrast agent in patients with abdominal pain", ACAD RADIOL, 8(3), 2001, pp. 234-242

Abstract

Rationale and Objectives. The authors performed this study to compare the cost and diagnostic abilities of ultrasound (US) performed with and withoutthe use of an oral contrast material recently approved by the U.S. Food and Drug Administration. Materials and Methods. An interactive decision-analytic model was constructed to compare US performed with and without contrast material (SonoRx, Bracco Diagnostics) for the evaluation of patients with abdominal pain who were suspected of having pancreatic disease. The model considered all resources that might be used to evaluate a patient suspected of having pancreatic disease leg, US, computed tomography [CT], endoscopic retrograde cholangiopancreatography, fine-needle aspiration biopsy, and open biopsy). The literature and an expert panel were the clinical data sources. Cost estimates werebased on Medicare and non-Medicare reimbursements. The primary cost-effectiveness measure was the cost to achieve a diagnosis. Results. SonoRx-enhanced US was less expensive than unenhanced US ($714 vs$808, respectively, with Medicare costs; $1,612 vs $1,878. respectively, with non-Medicare costs) and as effective (0.785 vs 0.782, respectively). SonoRx-enhanced US was more cost-effective than unenhanced US ($909 vs $1,034, respectively, with Medicare costs; $2,052 vs $2,401, respectively, with non-Medicare costs). This relationship was maintained throughout extensive sensitivity analyses. Conclusion. SonoRx-enhanced US is more cost-effective than unenhanced US, primarily because it avoids the need for CT. CT may be avoided owing to thehigher probability of obtaining optimal US scans with oral contrast material.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/21 alle ore 02:44:57